Danaher (NYSE:DHR – Get Free Report) released its quarterly earnings results on Tuesday. The conglomerate reported $1.92 earnings per share for the quarter, beating analysts’ consensus estimates of $1.72 by $0.20, Briefing.com reports. The business had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.62 billion. Danaher had a net margin of 17.26% and a return on equity of 12.25%. Danaher’s revenue for the quarter was down 2.6% on a year-over-year basis. During the same quarter last year, the firm earned $2.36 EPS.
Danaher Price Performance
NYSE:DHR traded down $3.36 on Wednesday, reaching $249.75. The stock had a trading volume of 1,103,403 shares, compared to its average volume of 2,755,977. The company has a market capitalization of $184.95 billion, a P/E ratio of 39.08, a price-to-earnings-growth ratio of 3.96 and a beta of 0.83. Danaher has a 1-year low of $182.09 and a 1-year high of $259.00. The company has a quick ratio of 1.37, a current ratio of 1.68 and a debt-to-equity ratio of 0.31. The stock has a fifty day moving average price of $248.95 and a 200-day moving average price of $230.64.
Danaher Increases Dividend
The company also recently declared a quarterly dividend, which will be paid on Friday, April 26th. Shareholders of record on Thursday, March 28th will be given a $0.27 dividend. The ex-dividend date is Wednesday, March 27th. This is a positive change from Danaher’s previous quarterly dividend of $0.24. This represents a $1.08 dividend on an annualized basis and a yield of 0.43%. Danaher’s payout ratio is 16.90%.
Insider Buying and Selling at Danaher
Analyst Upgrades and Downgrades
Several brokerages recently commented on DHR. Barclays lifted their target price on shares of Danaher from $260.00 to $270.00 and gave the stock an “equal weight” rating in a report on Wednesday. Raymond James lifted their target price on shares of Danaher from $240.00 to $270.00 and gave the stock an “outperform” rating in a report on Wednesday, January 31st. KeyCorp lifted their target price on shares of Danaher from $260.00 to $290.00 and gave the stock an “overweight” rating in a report on Thursday, February 1st. Royal Bank of Canada lifted their target price on shares of Danaher from $254.00 to $282.00 and gave the stock an “outperform” rating in a report on Wednesday, January 31st. Finally, HSBC upgraded shares of Danaher from a “hold” rating to a “buy” rating and lifted their target price for the stock from $250.00 to $280.00 in a report on Wednesday, April 17th. Six equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $268.67.
Check Out Our Latest Report on Danaher
About Danaher
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Read More
- Five stocks we like better than Danaher
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- High-Yield Texas Instruments Could Hit New Highs Soon
- Upcoming IPO Stock Lockup Period, Explained
- Pagaya Technologies: An AI Fintech That Insiders Are Buying
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.